Valuation: EyePoint, Inc.

Market Cap 420M 360M 337M 308M 581M 40.2B 587M 3.98B 1.55B 20.19B 1.58B 1.54B 66.79B P/E 2026 *
-1.32x
P/E 2027 * -1.83x
Enterprise Value 97.06M 83.18M 77.82M 71.14M 134M 9.29B 136M 921M 358M 4.67B 364M 357M 15.44B EV / Sales 2026 *
56.4x
EV / Sales 2027 * 5.88x
Free-Float
96.41%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: EyePoint, Inc.

1 day-8.46%
Current month-60.24%
1 month-60.05%
3 months-62.34%
6 months-71.44%
Current year-73.34%
1 week 4.87
Extreme 4.87
6.34
1 month 3.95
Extreme 3.95
14.76
Current year 3.95
Extreme 3.95
18.87
1 year 3.95
Extreme 3.95
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
40.2
Manager TitleAgeSince
Chief Executive Officer 67 09/07/2023
Director of Finance/CFO 61 13/11/2019
Chief Tech/Sci/R&D Officer 43 03/03/2024
Director TitleAgeSince
Director/Board Member 67 09/07/2023
Chairman 77 09/09/2018
Director/Board Member 73 24/10/2018
Date Insider Type Main position Quantity % Market Cap.
18/08/26 Buy

Director

10,600 0.0126%
10/07/26 Fiscal year

Chief Executive Officer

41,393 0.0494%
30/06/26 Fiscal year

Chief Technology Officer

14,625 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-8.46%0.00%-58.83%-57.69% 420M
-0.67%+5.39%+75.21%+127.54% 1,111B
+1.04%+4.07%+52.29%+65.39% 658B
-0.17%+5.67%+25.60%+80.40% 467B
-1.38%+4.02%+41.64%+42.38% 369B
-0.52%+2.72%+24.32%+41.06% 301B
-1.06%+4.76%+1.19%+12.65% 256B
+1.03%+5.83%+51.11%+72.96% 240B
-0.53%+2.34%-17.77%-53.66% 207B
+0.42%+5.63%+27.86%+92.24% 182B
Average -1.03%-2.18%+22.26%+42.33% 379.14B
Weighted average by Cap. -0.23%+4.88%+43.93%+72.99%

Financials

2026 *2027 *
Net sales 1.72M 1.47M 1.38M 1.26M 2.38M 165M 2.4M 16.32M 6.35M 82.72M 6.46M 6.32M 274M 17.92M 15.36M 14.37M 13.14M 24.79M 1.72B 25.05M 170M 66.11M 862M 67.29M 65.83M 2.85B
Net income -345M -295M -276M -253M -477M -33B -482M -3.27B -1.27B -16.57B -1.29B -1.27B -54.82B -292M -250M -234M -214M -404M -27.96B -408M -2.77B -1.08B -14.04B -1.1B -1.07B -46.46B
Net Debt -323M -277M -259M -237M -446M -30.91B -451M -3.06B -1.19B -15.52B -1.21B -1.19B -51.35B -314M -269M -252M -230M -435M -30.11B -440M -2.98B -1.16B -15.12B -1.18B -1.16B -50.02B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
24/08/26 US$4.870 -8.46% 4,155,639
21/08/26 US$5.320 -1.48% 8,186,380
20/08/26 US$5.400 -14.29% 7,406,287
19/08/26 US$6.300 +15.17% 8,792,924
18/08/26 US$5.470 +12.32% 16,238,028
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
4.870USD
Average target price
27.36USD
Spread / Average Target
+461.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock